Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, an extensive safety database, and convenient dosing to improve the lives of patients suffering from drug-resistant seizures and neuropsychiatric disorders.



CDKL5 Congress

6/2/17 - 6/3/17 | Rome

Jefferies Global Healthcare Conference

6/6/17 - 6/9/17

JMP Securities Life Sciences Conference

6/20/17 - 6/21/17 | New York, NY

More Events >

Clinical Trials

Physicians and patients learn more about ganaxolone and Marinus Pharmaceuticals’ clinical trials here.

View Pipeline >

Follow Us on Twitter

Rare Diseases's Twitter avatar
Rare Diseases

Dr. Masuoka from @MarinusPharma talking at AEDD meeting about CDKL5 and #rare #epilepsies #RareDiseases t.co/X7qQWNhrR8

Retweeted by Marinus Pharma
Show Media
Tweet Media